Immunology Investment Advisory Board
Immunology Investment Advisory Board
The Client
Top 10 pharma company
The Need
To explore emerging and novel therapeutic strategies within immunology late pre-clinical or early-phase clinical programs and to consider potential partnership opportunities.
The Action
Two 4-hour virtual advisory board meetings were held, where external advisors presented two immunology assets that might be of interest to the pharmaceutical company. After each asset was presented, questions were answered from other external advisors and from the pharmaceutical company. Assets were also critiqued by participants. My role was to document the discussion of over 25 participants.
The Outcome
A 21,000 word meeting report to facilitate investment decision-making.
Senior Account Director
“A comprehensive report on a complex set of assets – it included everything the company needs to make an informed investment decision.”
A comprehensive report on a complex set of assets – it included everything the company needs to make an informed investment decision.
The client
Top 10 pharma company
Senior Account Director
The need
To explore emerging and novel therapeutic strategies within immunology late pre-clinical or early-phase clinical programs and to consider potential partnership opportunities.
The action
Two 4-hour virtual advisory board meetings were held, where external advisors presented two immunology assets that might be of interest to the pharmaceutical company. After each asset was presented, questions were answered from other external advisors and from the pharmaceutical company. Assets were also critiqued by participants. My role was to document the discussion of over 25 participants.
A 21,000 word meeting report to facilitate investment decision-making.